Outcome of Off-Label AREDS 2 Supplementation for the Treatment of Macular Degeneration in Non-Proliferative Idiopathic Type 2 Macular Telangiectasia

Outcome of Off-Label AREDS 2 Supplementation for the Treatment of Macular Degeneration in Non-Proliferative Idiopathic Type 2 Macular Telangiectasia

Tyler A Berger,1 Matthew W Manry,1,2 Lucas B Lindsell,1,2 James M Osher,1,2 Daniel M Miller,1,2 Robert E Foster,1,2 Christopher D Riemann,1,2 Michael R Petersen,1,2 Robert A Sisk1– 3 1Department of Ophthalmology, University of Cincinnati, Cincinnati, OH, USA; 2Cincinnati Eye Institute, Cin...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Berger TA, Manry MW, Lindsell LB, Osher JM, Miller DM, Foster RE, Riemann CD, Petersen MR, Sisk RA
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2021
Materias:
antioxidant
areds2
carotenoid supplementation
ellipsoid zone loss
lutein
idiopathic macular telangiectasia
macular telangiectasia
juxtafoveal macular telangiectasia
parafoveal telangiectasia
retinal vascular disease.
Ophthalmology
RE1-994
Acceso en línea:https://doaj.org/article/b54a859aabc144b6b64c320b371c802d
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Internet

https://doaj.org/article/b54a859aabc144b6b64c320b371c802d

Ejemplares similares